Not Approved (US) Longevity & Mitochondrial

Testagen

also known as: Testis peptide bioregulator, KEDG tetrapeptide (Khavinson testis)

A Khavinson testis bioregulator preparation — note that the synthetic tetrapeptide KEDG has been reported in different Khavinson-group publications under both the Testagen and Ventfort names, reflecting either genuine tissue-source overlap or inconsistent nomenclature in the primary literature. Evidence is Russian-language; Russian nutraceutical status only.

A testis-tissue-derived short peptide bioregulator in the Khavinson cytomedine series. The synthetic tetrapeptide Lys-Glu-Asp-Gly (KEDG) has been associated with Testagen in some Khavinson publications and with Ventfort (vascular) in others; this reflects either a shared active fragment across bioregulator preparations or inconsistent naming in the primary Khavinson literature. The encyclopedia treats Testagen and Ventfort as separate entries because they are marketed separately with different primary indications, but users should be aware that the underlying synthetic peptide is reported to be the same.

Mechanism of action

Proposed to support testis-axis aging and male reproductive decline under the Khavinson-framework tissue-specific gene-expression hypothesis. Molecular validation minimal.

Primary uses

Testis-axis aging support (Russian nutraceutical positioning)
Male reproductive aging adjunct (anecdotal / Russian clinical use)

Typical dosing

1–2 capsules 1–2 times daily in 20–30 day courses (oral)

Russian nutraceutical dosing. No controlled efficacy evidence.

Regulatory status

Not FDA- or EMA-approved. Russian nutraceutical status only.

References

[review] Khavinson VK, et al. "Peptide bioregulation of endocrine function and aging." Adv Gerontol, 2012;25:11-23 (Russian).
[review] Anisimov VN, Khavinson VK. "Peptide bioregulation of aging: results and prospects." Biogerontology, 2010;11:139-149.

Related peptides

Ventfort

The Khavinson vascular bioregulator, marketed in Russia for endothelial aging and microcirculation support. Associated with the synthetic KEDG tetrapeptide in some Khavinson-group publications. Russian-language evidence base only; not FDA/EMA approved.

Prostamax

A Khavinson prostate bioregulator preparation marketed in Russia for prostate aging, with the synthetic KEDP tetrapeptide (Prostagen) as its characterized active fragment. Russian-language evidence base; no FDA/EMA status; no independent Western clinical replication.

Epithalon

A synthetic pineal tetrapeptide from the Khavinson group (St. Petersburg) — the only peptide with published data claiming telomerase activation and telomere elongation in human cell models.

Disclaimer

This entry is for educational purposes only and does not constitute medical advice. Dosing information reflects published regulatory or research data and is not a recommendation. Many compounds described here are not approved for human use in the United States. Consult a licensed medical professional before considering any peptide therapy.